Could well be Joe. See except from capital raising presentation...

Could well be Joe.
See except from capital raising presentation 21 June 2021. No updates on AIPAC P3 trial since.

Marc may be awaiting final OS data results (SITC - Nov) this time - as some may remember a small registrational trial was planned pre AIPAC PFS readout early last year. Didn't happen due to non-statistical benefit data v chemo.

OS data (especially in 2 sub-sets) has significantly improved chances of efti in combo with chemo becoming a SOC within 2-3 years.

Very rare for a small biotech to take a drug all the way through a P3 trial (500 patients - median cost per patient $50k US).

IMO - wont happen. Enter BMS stage left and possibly Merck stage right???

Post Transaction - Funded to Q4 20231
❑ Phase III Registrational Trial: in Metastatic Breast
Cancer (based on AIPAC).
❑ with 500 patients
❑ 90% power, alpha=0.05 and HR <= 0.7
❑ Overall Survival primary endpoint
❑ Phase II Trial: NSCLC
❑ 80 patients to test e.g. anti-PD1 + chemo + efti
combination
❑ 2* IITs with up to 40 pts each
❑ Commence process characterization and process
validation for efti commercial manufacturing
❑ Regulatory interactions with FDA and EMA
❑ IMP761: IND package
❑ Increase of staff and other operational costs